James is the CEO of LabGenius, a next-generation antibody discovery company. 

LabGenius has pioneered the development of an ML-driven protein engineering platform that’s capable of designing, conducting and critically learning from its own experiments. 

As CEO, James has raised >$70M in financing from top-tier VCs (e.g. M Ventures, Octopus Ventures, Lux Capital, Obvious Ventures, Atomico and Kindred) and struck R&D deals with top pharma companies like Sanofi. 

Prior to founding LabGenius, James completed a PhD at Imperial College where he developed novel methods for re-engineering protein nanocages for targeted drug delivery.